<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189745</url>
  </required_header>
  <id_info>
    <org_study_id>MENACWY-TT-101</org_study_id>
    <secondary_id>C0921005</secondary_id>
    <secondary_id>2013-001512-29</secondary_id>
    <secondary_id>116724</secondary_id>
    <nct_id>NCT03189745</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).</brief_title>
  <official_title>A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED 11-17 YEARS RECEIVED EITHER MENACWY-TT VACCINE (NIMENRIX(REGISTERED)) OR MENCEVAX ACWY(REGISTERED).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the immunogenicity, reactogenicity and safety of a booster dose of&#xD;
      MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received&#xD;
      either MenACWY-TT vaccine (Nimenrix) or Mencevax ACWY&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">April 11, 2018</completion_date>
  <primary_completion_date type="Actual">April 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination</measure>
    <time_frame>1 month after booster vaccination</time_frame>
    <description>Serogroups included: Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY). The rSBA titer levels greater than or equal to (&gt;=) 1:32 for initially seronegative participants and at least four-fold increase in rSBA titer levels for initially seropositive participants, 1 month after booster vaccination were defined as booster response to meningococcal antigens and reported in this outcome measure. Initially seronegative participants were defined as participants with pre-vaccination rSBA titer levels below 1:8 and initially seropositive participants were defined as participants with pre-vaccination rSBA titer &gt;=1:8. Data reported below is including both seropositive and seronegative participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With rSBA Titer Levels &gt;=1:8 and &gt;=1:128 for Each of the 4 Serogroups Before Booster Vaccination and 1 Month After Booster Vaccination</measure>
    <time_frame>Before booster vaccination, 1 month after booster vaccination (Vac)</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rSBA Geometric Mean Titers for Each of the 4 Serogroups Before Booster Vaccination and 1 Month After Booster Vaccination</measure>
    <time_frame>Before booster vaccination, 1 month after booster vaccination</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA titers were expressed as the reciprocal of the highest serum last dilution resulting in at least 50 percentage (%) reduction of meningococcal colony-forming units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Tetanus Toxoid (Anti-TT) Concentrations &gt;=0.1 International Units Per Millilitre (IU/mL), &gt;=1.0 IU/mL Before Booster Vaccination and 1 Month After Booster Vaccination</measure>
    <time_frame>Before booster vaccination, 1 month after booster vaccination</time_frame>
    <description>Tetanus toxoid (TT) was used as carrier in tetravalent meningococcal ACWY conjugate vaccine. Percentage of participants with anti-TT concentration &gt;=0.1 IU/mL, &gt;=1.0 IU/mL were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Anti-Tetanus Toxoid Before Booster Vaccination and 1 Month After Booster Vaccination</measure>
    <time_frame>Before booster vaccination, 1 month after booster vaccination</time_frame>
    <description>TT was used as carrier in tetravalent meningococcal ACWY conjugate vaccine. The GMCs calculations was performed by taking the anti-log of the mean of the log concentration transformations. Antibody (Anti-TT) concentrations below the cut-off value (0.1 IU/mL) of the assay was given an arbitrary value of half the cut-off value for the purpose of GMC calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Local and General Adverse Events Within 4 Days After Booster Vaccination</measure>
    <time_frame>Within 4 days post booster vaccination (Day 0 to Day 3)</time_frame>
    <description>Solicited local reactions included pain, redness and swelling. Pain graded as: (0= none, 1= mild, not interfered/prevented normal activity, 2= moderate, painful when limb moved/interfered with normal activity, 3= severe, significant pain at rest/ prevented normal activity). Redness and swelling scored as:0= None, 1= 0 to less than or equal to (&lt;=) 20 millimeter (mm), 2= greater than (&gt;) 20 to &lt;=50 mm, 3=&gt;50 mm. Solicited general reactions: headache, fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea /abdominal pain) graded as (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe / prevented normal activity). Fever categorized as: 0= less than (&lt;) 37.5 degree Celsius (C), 1= &gt;=37.5 to &lt;=38.5 degree C, 2= &gt;38.5 to &lt;=39.5 degree C, and 3= &gt;39.5 degree C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Unsolicited Adverse Events (AEs) Within 31 Days After Booster Vaccination</measure>
    <time_frame>31 days after booster vaccination (Day 0 to Day 30)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. And any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs), Guillain-Barre Syndrome (GBS) and New Onset of Chronic Illnesses (NOCI) Within 31 Days After Booster Vaccination</measure>
    <time_frame>Within 31 days after booster vaccination (Day 0 to Day 30)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. GBS is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system-the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently. All occurrences of GBS has to be reported as an SAE. New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SAEs Related to Primary Vaccination and Any Events Related to Lack of Vaccine Efficacy After 10 Years of Primary Vaccination</measure>
    <time_frame>10 years after primary vaccination</time_frame>
    <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Occurrence of SAEs related to primary vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the participant's last visit in the primary study 109069 (NCT00464815) or in persistence study 112148 (NCT00974363); extension study: 109069 (NCT00464815) at Year 2, 3, 4, 5 after primary vaccination until entry in study MenACWYTT-101, which is extension of study 109069 (NCT00464815), 10 years post primary vaccination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With rSBA Titer Levels &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups at 10 Years After Primary Vaccination</measure>
    <time_frame>10 years after primary vaccination</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers With rSBA For Each of the 4 Serogroups at 10 Years After Primary Vaccination</measure>
    <time_frame>10 years after primary vaccination</time_frame>
    <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA titers were expressed as the reciprocal of the highest serum last dilution resulting in at least 50% reduction of meningococcal colony-forming units.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Meningococcal ACWY Disease</condition>
  <arm_group>
    <arm_group_label>MenACWY-TT Booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 year booster dose of MenACWY</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-TT</intervention_name>
    <description>Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY</description>
    <arm_group_label>MenACWY-TT Booster</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, can and will comply, with the&#xD;
             requirements of the protocol (e.g. completion of the diary cards, return for follow-up&#xD;
             visits).&#xD;
&#xD;
          -  Written informed consent obtained from the subject prior to performing any study&#xD;
             specific procedure.&#xD;
&#xD;
          -  Healthy male or female subjects as established by medical history and history-directed&#xD;
             physical examination before entering into the study.&#xD;
&#xD;
          -  Having completed the vaccination in study MenACWY-TT-036 (109069) as per protocol.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
&#xD;
          -  Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral&#xD;
             ovariectomy or post-menopause.&#xD;
&#xD;
        Please refer to the GLOSSARY OF TERMS for the definitions of menarche and post-menopause.&#xD;
&#xD;
          -  Male subjects able to father children and female subjects of childbearing potential&#xD;
             (including females who have had tubal ligation) and at risk for pregnancy may be&#xD;
             enrolled in the study, if the subject:&#xD;
&#xD;
          -  has practiced adequate contraception for 30 days prior to vaccination, and&#xD;
&#xD;
          -  has a negative pregnancy test on the day of vaccination (for females only), and&#xD;
&#xD;
          -  has agreed to continue adequate contraception during the entire treatment period and&#xD;
             for 2 months after completion of the vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccine within 30 days preceding the dose of study vaccine, or planned use&#xD;
             during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants&#xD;
             or other immune-modifying drugs within six months prior to the vaccine dose. For&#xD;
             corticosteroids, this will be 10 mg/day prednisone, or equivalent. Inhaled, topical,&#xD;
             and intra-articular steroids are allowed.&#xD;
&#xD;
          -  Administration of a vaccine not foreseen by the study protocol within the period&#xD;
             starting 30 days before and ending 30 days after the study vaccine dose, with the&#xD;
             exception of a licensed inactivated influenza vaccine which can be administered at any&#xD;
             time during the study according to the local recommendations.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the study vaccination or planned administration during the booster&#xD;
             vaccination phase of the study (i.e. between Visit 1 and Visit 2).&#xD;
&#xD;
          -  Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational vaccine/product (pharmaceutical product or device).&#xD;
&#xD;
          -  Previous vaccination with meningococcal vaccine except the meningococcal vaccination&#xD;
             received in the MenACWY-TT-036 study.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital&#xD;
             or secondary), including human immunodeficiency virus infection, based on medical&#xD;
             history and physical examination (no laboratory testing required).&#xD;
&#xD;
          -  Family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the vaccine, and history of serious allergic reaction (anaphylaxis) following the&#xD;
             administration of vaccine(s).&#xD;
&#xD;
          -  Major congenital defects or serious chronic illness.&#xD;
&#xD;
          -  History of any neurological disorders or seizures, including GBS. History of a simple,&#xD;
             single febrile seizure is permitted.&#xD;
&#xD;
          -  Acute disease and/or fever at the time of vaccination.&#xD;
&#xD;
          -  Fever is defined as temperature ≥ 37.5°C for oral, axillary or tympanic route, or ≥&#xD;
             38.0°C for rectal route. The preferred route for recording temperature in this study&#xD;
             will be oral.&#xD;
&#xD;
          -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory&#xD;
             infection) without fever may be vaccinated at the discretion of the investigator.&#xD;
&#xD;
          -  Subjects who are investigational site staff members directly involved in the conduct&#xD;
             of the study and their family members, site staff members otherwise supervised by the&#xD;
             investigator, or subjects who are Pfizer employees directly involved in the conduct of&#xD;
             the study.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions.&#xD;
&#xD;
          -  Male subjects able to father children who are planning to discontinue contraceptive&#xD;
             precautions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Metro Manila</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=MENACWY-TT-101</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03189745/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03189745/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03189745/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who received either MenACWY-TT (NIMENRIX) or Mencevax ACWY vaccine in study 109069 (NCT00464815) were administered a MenACWY-TT booster vaccination in this study and evaluated for immunogenicity, reactogenicity and safety parameters.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACWY-TT Group</title>
          <description>Participants received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
        </group>
        <group group_id="P2">
          <title>MenPS Group</title>
          <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Conflict in work schedule of participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population included all participants enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>ACWY-TT Group</title>
          <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
        </group>
        <group group_id="B2">
          <title>MenPS Group</title>
          <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.2" spread="1.9"/>
                    <measurement group_id="B2" value="24.0" spread="2.0"/>
                    <measurement group_id="B3" value="24.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian - South East Asian heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination</title>
        <description>Serogroups included: Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY). The rSBA titer levels greater than or equal to (&gt;=) 1:32 for initially seronegative participants and at least four-fold increase in rSBA titer levels for initially seropositive participants, 1 month after booster vaccination were defined as booster response to meningococcal antigens and reported in this outcome measure. Initially seronegative participants were defined as participants with pre-vaccination rSBA titer levels below 1:8 and initially seropositive participants were defined as participants with pre-vaccination rSBA titer &gt;=1:8. Data reported below is including both seropositive and seronegative participants.</description>
        <time_frame>1 month after booster vaccination</time_frame>
        <population>Booster according-to-protocol(ATP)Cohort for immunogenicity: met booster ATP cohort for safety, comply procedures in protocol, meeting visit interval from primary vaccination(vac) in 109069 to booster vac,blood sampling intervals, had assay results with no vac before post booster vac blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination</title>
          <description>Serogroups included: Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY). The rSBA titer levels greater than or equal to (&gt;=) 1:32 for initially seronegative participants and at least four-fold increase in rSBA titer levels for initially seropositive participants, 1 month after booster vaccination were defined as booster response to meningococcal antigens and reported in this outcome measure. Initially seronegative participants were defined as participants with pre-vaccination rSBA titer levels below 1:8 and initially seropositive participants were defined as participants with pre-vaccination rSBA titer &gt;=1:8. Data reported below is including both seropositive and seronegative participants.</description>
          <population>Booster according-to-protocol(ATP)Cohort for immunogenicity: met booster ATP cohort for safety, comply procedures in protocol, meeting visit interval from primary vaccination(vac) in 109069 to booster vac,blood sampling intervals, had assay results with no vac before post booster vac blood draw.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="74.6" upper_limit="87.1"/>
                    <measurement group_id="O2" value="84.3" lower_limit="71.4" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="82.3" upper_limit="92.8"/>
                    <measurement group_id="O2" value="66.7" lower_limit="52.1" upper_limit="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="91.3" upper_limit="98.2"/>
                    <measurement group_id="O2" value="94.1" lower_limit="83.8" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="80.9" upper_limit="91.8"/>
                    <measurement group_id="O2" value="90.2" lower_limit="78.6" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With rSBA Titer Levels &gt;=1:8 and &gt;=1:128 for Each of the 4 Serogroups Before Booster Vaccination and 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>Before booster vaccination, 1 month after booster vaccination (Vac)</time_frame>
        <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069(NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With rSBA Titer Levels &gt;=1:8 and &gt;=1:128 for Each of the 4 Serogroups Before Booster Vaccination and 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069(NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA: &gt;=1:8; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="78.8" upper_limit="90.3"/>
                    <measurement group_id="O2" value="80.4" lower_limit="66.9" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;=1:8;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:8; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="84.5" upper_limit="94.2"/>
                    <measurement group_id="O2" value="82.4" lower_limit="69.1" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:8;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:8; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" lower_limit="64.0" upper_limit="78.4"/>
                    <measurement group_id="O2" value="43.1" lower_limit="29.3" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135:&gt;=1:8;1month after booster vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:8; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="85.2" upper_limit="94.7"/>
                    <measurement group_id="O2" value="49.0" lower_limit="34.8" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:8;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.0" lower_limit="89.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;=1:28; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="74.6" upper_limit="87.1"/>
                    <measurement group_id="O2" value="76.5" lower_limit="62.5" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA:&gt;=1:28;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:28; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="69.9" upper_limit="83.4"/>
                    <measurement group_id="O2" value="62.7" lower_limit="48.1" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC:&gt;=1:28;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:28; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="56.9" upper_limit="72.1"/>
                    <measurement group_id="O2" value="25.5" lower_limit="14.3" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135:&gt;=1:28;1month after booster vac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.0" lower_limit="89.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:28; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="78.8" upper_limit="90.3"/>
                    <measurement group_id="O2" value="39.2" lower_limit="25.8" upper_limit="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY:&gt;=1:28;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.1" lower_limit="86.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>rSBA Geometric Mean Titers for Each of the 4 Serogroups Before Booster Vaccination and 1 Month After Booster Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA titers were expressed as the reciprocal of the highest serum last dilution resulting in at least 50 percentage (%) reduction of meningococcal colony-forming units.</description>
        <time_frame>Before booster vaccination, 1 month after booster vaccination</time_frame>
        <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069 (NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>rSBA Geometric Mean Titers for Each of the 4 Serogroups Before Booster Vaccination and 1 Month After Booster Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA titers were expressed as the reciprocal of the highest serum last dilution resulting in at least 50 percentage (%) reduction of meningococcal colony-forming units.</description>
          <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069 (NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.4" lower_limit="181.4" upper_limit="340.2"/>
                    <measurement group_id="O2" value="142.7" lower_limit="80.5" upper_limit="252.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3760.1" lower_limit="3268.3" upper_limit="4325.9"/>
                    <measurement group_id="O2" value="2956.0" lower_limit="2040.5" upper_limit="4282.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.2" lower_limit="181.6" upper_limit="328.5"/>
                    <measurement group_id="O2" value="177.4" lower_limit="86.1" upper_limit="365.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8697.7" lower_limit="7391.2" upper_limit="10235.1"/>
                    <measurement group_id="O2" value="3879.3" lower_limit="2714.6" upper_limit="5543.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.5" lower_limit="97.6" upper_limit="217.1"/>
                    <measurement group_id="O2" value="16.4" lower_limit="9.2" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11243.4" lower_limit="9366.8" upper_limit="13496.0"/>
                    <measurement group_id="O2" value="3674.0" lower_limit="2353.9" upper_limit="5734.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446.5" lower_limit="332.7" upper_limit="599.1"/>
                    <measurement group_id="O2" value="32.9" lower_limit="17.1" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY; 1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7584.8" lower_limit="6748.4" upper_limit="8524.7"/>
                    <measurement group_id="O2" value="3295.5" lower_limit="1998.7" upper_limit="5433.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Tetanus Toxoid (Anti-TT) Concentrations &gt;=0.1 International Units Per Millilitre (IU/mL), &gt;=1.0 IU/mL Before Booster Vaccination and 1 Month After Booster Vaccination</title>
        <description>Tetanus toxoid (TT) was used as carrier in tetravalent meningococcal ACWY conjugate vaccine. Percentage of participants with anti-TT concentration &gt;=0.1 IU/mL, &gt;=1.0 IU/mL were summarized.</description>
        <time_frame>Before booster vaccination, 1 month after booster vaccination</time_frame>
        <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069 (NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Tetanus Toxoid (Anti-TT) Concentrations &gt;=0.1 International Units Per Millilitre (IU/mL), &gt;=1.0 IU/mL Before Booster Vaccination and 1 Month After Booster Vaccination</title>
          <description>Tetanus toxoid (TT) was used as carrier in tetravalent meningococcal ACWY conjugate vaccine. Percentage of participants with anti-TT concentration &gt;=0.1 IU/mL, &gt;=1.0 IU/mL were summarized.</description>
          <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069 (NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=0.1 IU/mL; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="80.2" upper_limit="91.3"/>
                    <measurement group_id="O2" value="54.9" lower_limit="40.3" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=0.1 IU/mL;1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="95.6" upper_limit="99.9"/>
                    <measurement group_id="O2" value="96.1" lower_limit="86.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.0 IU/mL; Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="30.8" upper_limit="46.2"/>
                    <measurement group_id="O2" value="27.5" lower_limit="15.9" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1.0 IU/mL; 1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0" lower_limit="86.7" upper_limit="95.7"/>
                    <measurement group_id="O2" value="82.4" lower_limit="69.1" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMCs) of Anti-Tetanus Toxoid Before Booster Vaccination and 1 Month After Booster Vaccination</title>
        <description>TT was used as carrier in tetravalent meningococcal ACWY conjugate vaccine. The GMCs calculations was performed by taking the anti-log of the mean of the log concentration transformations. Antibody (Anti-TT) concentrations below the cut-off value (0.1 IU/mL) of the assay was given an arbitrary value of half the cut-off value for the purpose of GMC calculation.</description>
        <time_frame>Before booster vaccination, 1 month after booster vaccination</time_frame>
        <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069 (NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Anti-Tetanus Toxoid Before Booster Vaccination and 1 Month After Booster Vaccination</title>
          <description>TT was used as carrier in tetravalent meningococcal ACWY conjugate vaccine. The GMCs calculations was performed by taking the anti-log of the mean of the log concentration transformations. Antibody (Anti-TT) concentrations below the cut-off value (0.1 IU/mL) of the assay was given an arbitrary value of half the cut-off value for the purpose of GMC calculation.</description>
          <population>Booster ATP Cohort for immunogenicity: met requirements of booster ATP cohort for safety, comply procedures in protocol included meeting visit interval from primary vaccination in 109069 (NCT00464815) to booster vaccination and blood sampling intervals, had assay results with no vaccine administered before post booster vaccination blood draw.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.608" lower_limit="0.476" upper_limit="0.775"/>
                    <measurement group_id="O2" value="0.252" lower_limit="0.154" upper_limit="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.057" lower_limit="4.274" upper_limit="5.984"/>
                    <measurement group_id="O2" value="5.115" lower_limit="3.073" upper_limit="8.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Local and General Adverse Events Within 4 Days After Booster Vaccination</title>
        <description>Solicited local reactions included pain, redness and swelling. Pain graded as: (0= none, 1= mild, not interfered/prevented normal activity, 2= moderate, painful when limb moved/interfered with normal activity, 3= severe, significant pain at rest/ prevented normal activity). Redness and swelling scored as:0= None, 1= 0 to less than or equal to (&lt;=) 20 millimeter (mm), 2= greater than (&gt;) 20 to &lt;=50 mm, 3=&gt;50 mm. Solicited general reactions: headache, fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea /abdominal pain) graded as (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe / prevented normal activity). Fever categorized as: 0= less than (&lt;) 37.5 degree Celsius (C), 1= &gt;=37.5 to &lt;=38.5 degree C, 2= &gt;38.5 to &lt;=39.5 degree C, and 3= &gt;39.5 degree C.</description>
        <time_frame>Within 4 days post booster vaccination (Day 0 to Day 3)</time_frame>
        <population>Booster total vaccinated cohort (TVC) for safety included all vaccinated participants in study 109069 (NCT00464815) with a MenACWY-TT booster vaccine administration documented in study MENACWY-TT-101. Here, &quot;Overall Number of Participants Analyzed&quot; (N) signifies number of participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local and General Adverse Events Within 4 Days After Booster Vaccination</title>
          <description>Solicited local reactions included pain, redness and swelling. Pain graded as: (0= none, 1= mild, not interfered/prevented normal activity, 2= moderate, painful when limb moved/interfered with normal activity, 3= severe, significant pain at rest/ prevented normal activity). Redness and swelling scored as:0= None, 1= 0 to less than or equal to (&lt;=) 20 millimeter (mm), 2= greater than (&gt;) 20 to &lt;=50 mm, 3=&gt;50 mm. Solicited general reactions: headache, fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea /abdominal pain) graded as (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe / prevented normal activity). Fever categorized as: 0= less than (&lt;) 37.5 degree Celsius (C), 1= &gt;=37.5 to &lt;=38.5 degree C, 2= &gt;38.5 to &lt;=39.5 degree C, and 3= &gt;39.5 degree C.</description>
          <population>Booster total vaccinated cohort (TVC) for safety included all vaccinated participants in study 109069 (NCT00464815) with a MenACWY-TT booster vaccine administration documented in study MENACWY-TT-101. Here, &quot;Overall Number of Participants Analyzed&quot; (N) signifies number of participants evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Unsolicited Adverse Events (AEs) Within 31 Days After Booster Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. And any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
        <time_frame>31 days after booster vaccination (Day 0 to Day 30)</time_frame>
        <population>Booster TVC for safety included all vaccinated participants in study 109069 (NCT00464815) with a MenACWY-TT booster vaccine administration documented in study MENACWY-TT-101.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unsolicited Adverse Events (AEs) Within 31 Days After Booster Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. And any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
          <population>Booster TVC for safety included all vaccinated participants in study 109069 (NCT00464815) with a MenACWY-TT booster vaccine administration documented in study MENACWY-TT-101.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="5.5" upper_limit="14.8"/>
                    <measurement group_id="O2" value="15.3" lower_limit="7.2" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs), Guillain-Barre Syndrome (GBS) and New Onset of Chronic Illnesses (NOCI) Within 31 Days After Booster Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. GBS is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system-the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently. All occurrences of GBS has to be reported as an SAE. New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>Within 31 days after booster vaccination (Day 0 to Day 30)</time_frame>
        <population>Booster TVC for safety included all vaccinated participants in study 109069 (NCT00464815) with a MenACWY-TT booster vaccine administration documented in study MENACWY-TT-101.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs), Guillain-Barre Syndrome (GBS) and New Onset of Chronic Illnesses (NOCI) Within 31 Days After Booster Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. GBS is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system-the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently. All occurrences of GBS has to be reported as an SAE. New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>Booster TVC for safety included all vaccinated participants in study 109069 (NCT00464815) with a MenACWY-TT booster vaccine administration documented in study MENACWY-TT-101.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SAEs Related to Primary Vaccination and Any Events Related to Lack of Vaccine Efficacy After 10 Years of Primary Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Occurrence of SAEs related to primary vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the participant's last visit in the primary study 109069 (NCT00464815) or in persistence study 112148 (NCT00974363); extension study: 109069 (NCT00464815) at Year 2, 3, 4, 5 after primary vaccination until entry in study MenACWYTT-101, which is extension of study 109069 (NCT00464815), 10 years post primary vaccination.</description>
        <time_frame>10 years after primary vaccination</time_frame>
        <population>The total cohort at Month 120 (10 years post primary vaccination) included all vaccinated participants from the vaccination of Study 109069 (NCT00464815) who return for the Month 120 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SAEs Related to Primary Vaccination and Any Events Related to Lack of Vaccine Efficacy After 10 Years of Primary Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Occurrence of SAEs related to primary vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the participant's last visit in the primary study 109069 (NCT00464815) or in persistence study 112148 (NCT00974363); extension study: 109069 (NCT00464815) at Year 2, 3, 4, 5 after primary vaccination until entry in study MenACWYTT-101, which is extension of study 109069 (NCT00464815), 10 years post primary vaccination.</description>
          <population>The total cohort at Month 120 (10 years post primary vaccination) included all vaccinated participants from the vaccination of Study 109069 (NCT00464815) who return for the Month 120 follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Events related to lack of vac efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With rSBA Titer Levels &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups at 10 Years After Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
        <time_frame>10 years after primary vaccination</time_frame>
        <population>ATP Cohort for Persistence at Month 120: participants who eligible in Study 109069 (NCT00464815), received primary vaccination with MenACWY-TT or Mencevax ACWY during Study 109069, had assay results for at least one tested antigen at Month 120, did not received a meningococcal vaccine not planned in Study 109069 before Month 120 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With rSBA Titer Levels &gt;=1:8 and &gt;=1:128 For Each of the 4 Serogroups at 10 Years After Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY.</description>
          <population>ATP Cohort for Persistence at Month 120: participants who eligible in Study 109069 (NCT00464815), received primary vaccination with MenACWY-TT or Mencevax ACWY during Study 109069, had assay results for at least one tested antigen at Month 120, did not received a meningococcal vaccine not planned in Study 109069 before Month 120 visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="78.2" upper_limit="89.8"/>
                    <measurement group_id="O2" value="81.1" lower_limit="68.0" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" lower_limit="84.5" upper_limit="94.3"/>
                    <measurement group_id="O2" value="83.0" lower_limit="70.2" upper_limit="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="64.2" upper_limit="78.5"/>
                    <measurement group_id="O2" value="41.5" lower_limit="28.1" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" lower_limit="85.3" upper_limit="94.8"/>
                    <measurement group_id="O2" value="49.1" lower_limit="35.1" upper_limit="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenA: &gt;=1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="74.1" upper_limit="86.7"/>
                    <measurement group_id="O2" value="77.4" lower_limit="63.8" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC: &gt;=1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="70.1" upper_limit="83.5"/>
                    <measurement group_id="O2" value="64.2" lower_limit="49.8" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135: &gt;=1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="57.2" upper_limit="72.3"/>
                    <measurement group_id="O2" value="24.5" lower_limit="13.8" upper_limit="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY: &gt;=1:128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="78.9" upper_limit="90.3"/>
                    <measurement group_id="O2" value="37.7" lower_limit="24.8" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers With rSBA For Each of the 4 Serogroups at 10 Years After Primary Vaccination</title>
        <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA titers were expressed as the reciprocal of the highest serum last dilution resulting in at least 50% reduction of meningococcal colony-forming units.</description>
        <time_frame>10 years after primary vaccination</time_frame>
        <population>ATP Cohort for Persistence at Month 120: participants who eligible in Study 109069 (NCT00464815), received primary vaccination with MenACWY-TT or Mencevax ACWY during Study 109069, had assay results for at least one tested antigen at Month 120, did not received a meningococcal vaccine not planned in Study 109069 before Month 120 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ACWY-TT Group</title>
            <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>MenPS Group</title>
            <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers With rSBA For Each of the 4 Serogroups at 10 Years After Primary Vaccination</title>
          <description>Serogroups included MenA, MenC, MenW-135 and MenY. rSBA titers were expressed as the reciprocal of the highest serum last dilution resulting in at least 50% reduction of meningococcal colony-forming units.</description>
          <population>ATP Cohort for Persistence at Month 120: participants who eligible in Study 109069 (NCT00464815), received primary vaccination with MenACWY-TT or Mencevax ACWY during Study 109069, had assay results for at least one tested antigen at Month 120, did not received a meningococcal vaccine not planned in Study 109069 before Month 120 visit.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA-MenA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.2" lower_limit="176.6" upper_limit="332.3"/>
                    <measurement group_id="O2" value="153.7" lower_limit="87.8" upper_limit="269.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.3" lower_limit="181.1" upper_limit="326.7"/>
                    <measurement group_id="O2" value="182.2" lower_limit="90.9" upper_limit="365.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenW-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.0" lower_limit="98.2" upper_limit="217.3"/>
                    <measurement group_id="O2" value="15.6" lower_limit="8.9" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA-MenY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446.9" lower_limit="333.6" upper_limit="598.5"/>
                    <measurement group_id="O2" value="31.6" lower_limit="16.8" upper_limit="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 31 days after booster vaccination (From Day 0 to Day 30). Solicited local and general reactions: Recorded by participants in e-diary within 4 days post booster vaccination (Day 0 to Day 3)</time_frame>
      <desc>All participants who received vaccine MenACWY-TT or Mencevax ACWY in study 109069 (NCT00464815) and received a MenACWY-TT booster dose in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACWY-TT Group</title>
          <description>Participants received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
        </group>
        <group group_id="E2">
          <title>MenPS Group</title>
          <description>Participants received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly as primary vaccination in study 109069 (NCT00464815) and then 10 years post primary vaccination received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly as booster vaccination. Participants were also evaluated for long-term persistence (of immune response and safety) at year 10 post primary vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection site erythema (redness)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection site pain (pain at injection site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection site swelling (swelling)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

